Falcon Point Capital Has Cut Its Ligand Pharmaceuticals (LGND) Holding; Kentucky First Federal Bancorp (KFFB)’s Sentiment Is 3

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Logo

Kentucky First Federal Bancorp (KFFB) investors sentiment increased to 3 in 2018 Q2. It’s up 2.67, from 0.33 in 2018Q1. The ratio has increased, as 3 active investment managers opened new or increased holdings, while 1 sold and decreased stakes in Kentucky First Federal Bancorp. The active investment managers in our database now possess: 194,834 shares, up from 192,857 shares in 2018Q1. Also, the number of active investment managers holding Kentucky First Federal Bancorp in top ten holdings was flat from 0 to 0 for the same number . Sold All: 0 Reduced: 1 Increased: 3 New Position: 0.

Falcon Point Capital Llc decreased Ligand Pharmaceuticals Inc. (LGND) stake by 29.48% reported in 2018Q2 SEC filing. Falcon Point Capital Llc sold 23,721 shares as Ligand Pharmaceuticals Inc. (LGND)’s stock rose 38.65%. The Falcon Point Capital Llc holds 56,747 shares with $11.76 million value, down from 80,468 last quarter. Ligand Pharmaceuticals Inc. now has $3.15B valuation. The stock decreased 3.04% or $4.64 during the last trading session, reaching $148.13. About 137,034 shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 86.03% since December 6, 2017 and is uptrending. It has outperformed by 70.41% the S&P500. Some Historical LGND News: 08/05/2018 – Ligand Pharmaceuticals 1Q Rev $56.2M; 22/03/2018 – LIGAND PHARMACEUTICALS SAYS ON MARCH 20, CO ENTERED INTO AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT, DATED FEB 16, 2012 WITH RETROPHIN, INC- SEC FILING; 07/03/2018 – Ligand Pharmaceuticals Sees 2018 Rev $184M; 11/04/2018 – ARBUTUS – GENEVANT AIMS FOR 5-10 PRODUCT CANDIDATES INTO CLINIC BY 2020 ACROSS RNAI, MRNA, GENE EDITING MODALITIES USING CO’S LNP, LIGAND CONJUGATE PLATFORMS; 06/03/2018 – LIGAND PHARMACEUTICALS – PER TERMS OF LICENSE AGREEMENT WITH ROIVANT, CO TO RECEIVE TOTAL POTENTIAL LICENSE & MILESTONE PAYMENTS OF UP TO $533.8 MLN; 11/05/2018 – Ligand to Participate in Upcoming Investor Conferences; 06/03/2018 – LIGAND PHARMACEUTICALS INC – SIGNED LICENSE AGREEMENT GRANTING ROIVANT SCIENCES EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE LGD-6972; 11/05/2018 – Ligand Pharma Presenting at Berenberg USA Conference May 24; 08/05/2018 – LIGAND PHARMA SEES FY ADJ EPS ABOUT $4.85, EST. $4.79; 07/03/2018 – LIGAND PHARMACEUTICALS SAYS UNDERREPORTED POTENTIAL AGGREGATE MILESTONE PAYMENTS RELATED TO LICENSE AGREEMENT WITH ROIVANT SCIENCES FOR LGD-6972

More notable recent Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) news were published by: Nasdaq.com which released: “What Lies in Store for Ligand (LGND) This Earnings Season? – Nasdaq” on November 06, 2018, also Nasdaq.com with their article: “Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View – Nasdaq” published on November 09, 2018, Seekingalpha.com published: “Ligand Pharmaceuticals beats by $0.29, beats on revenue – Seeking Alpha” on November 08, 2018. More interesting news about Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) were released by: Seekingalpha.com and their article: “Ligand in licensing pact with iMetabolic for OmniAb platform – Seeking Alpha” published on November 21, 2018 as well as Nasdaq.com‘s news article titled: “Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium – Nasdaq” with publication date: November 14, 2018.

Analysts await Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to report earnings on February, 20. They expect $0.99 earnings per share, down 3.88% or $0.04 from last year’s $1.03 per share. LGND’s profit will be $21.04M for 37.41 P/E if the $0.99 EPS becomes a reality. After $1.35 actual earnings per share reported by Ligand Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -26.67% negative EPS growth.

Among 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Ligand Pharmaceuticals had 5 analyst reports since June 21, 2018 according to SRatingsIntel. As per Wednesday, September 19, the company rating was maintained by H.C. Wainwright. Craig Hallum maintained it with “Buy” rating and $23000 target in Wednesday, June 27 report. Roth Capital downgraded the shares of LGND in report on Wednesday, August 8 to “Neutral” rating.

Investors sentiment increased to 1.11 in 2018 Q2. Its up 0.05, from 1.06 in 2018Q1. It is positive, as 16 investors sold LGND shares while 109 reduced holdings. 42 funds opened positions while 97 raised stakes. 22.99 million shares or 1.94% more from 22.56 million shares in 2018Q1 were reported. 199,085 are held by Dimensional Fund Advsrs Lp. Qs Investors Limited Liability Company reported 503 shares. Wealthtrust reported 0.03% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Raymond James Fincl Ser Advisors stated it has 0% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Kopp Inv Advisors Limited Liability Company reported 3.59% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). 51,083 are held by Rk Limited Com. Castleark Mngmt Ltd Liability holds 0.59% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 92,215 shares. The California-based Shelton Management has invested 0.03% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Summit Creek Advsr Limited Liability Company invested in 1.87% or 50,387 shares. Kepos Capital Ltd Partnership reported 30,096 shares stake. Deutsche State Bank Ag holds 302,152 shares. Hartford Inv Mngmt reported 0.01% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Tower Cap Lc (Trc) accumulated 15 shares. New York-based Jefferies Limited Liability has invested 0.05% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Keybank Association Oh stated it has 0% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND).

Falcon Point Capital Llc increased Jack In The Box Inc. (NASDAQ:JACK) stake by 6,224 shares to 158,750 valued at $13.51M in 2018Q2. It also upped Granite Construction (NYSE:GVA) stake by 23,474 shares and now owns 113,817 shares. Amag Pharmaceuticals Inc. (NASDAQ:AMAG) was raised too.

Since July 2, 2018, it had 0 insider buys, and 15 selling transactions for $49.00 million activity. Berkman Charles S also sold $4.95M worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Tuesday, September 4. Another trade for 3,335 shares valued at $850,292 was made by LAMATTINA JOHN L on Tuesday, September 4. $10.15 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was sold by Patel Sunil. Shares for $2.16M were sold by Davis Todd C on Thursday, August 16. $3.06 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was sold by FOEHR MATTHEW W on Tuesday, September 4. Another trade for 18,357 shares valued at $4.71M was sold by Korenberg Matthew E. The insider Aryeh Jason sold 27,942 shares worth $6.76 million.

The stock decreased 3.31% or $0.27 during the last trading session, reaching $7.89. About 12,170 shares traded or 207.56% up from the average. Kentucky First Federal Bancorp (KFFB) has declined 16.40% since December 6, 2017 and is downtrending. It has underperformed by 32.02% the S&P500. Some Historical KFFB News: 08/05/2018 – Kentucky First Federal Bancorp Releases Earnings; 08/05/2018 – KENTUCKY FIRST FEDERAL BANCORP KFFB.O QUARTERLY SHR $0.02; 19/04/2018 – DJ Kentucky First Federal Bancorp, Inst Holders, 1Q 2018 (KFFB); 08/05/2018 – Kentucky First Federal 3Q EPS 2c; 04/04/2018 Kentucky First Federal Bancorp Announces Payment of Quarterly Dividend

Kentucky First Federal Bancorp operates as the holding firm for First Federal Savings and Loan Association of Hazard, and Frankfort First Bancorp, Inc. that provide various banking services and products in the United States. The company has market cap of $66.34 million. The Company’s deposit products include passbook savings and certificate accounts, checking accounts, and individual retirement accounts. It has a 55.96 P/E ratio. The companyÂ’s loan portfolio comprises one- to four-family residential mortgage loans; construction loans; mortgage loans secured by multi-family property; nonresidential loans that are secured by commercial office buildings, churches, condominiums, and properties used for other purposes; commercial non-mortgage loans; and consumer loans, such as home equity lines of credit, loans secured by savings deposits, automobile loans, and unsecured or personal loans.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.